Glucagon-like peptide 1 receptor (GLP-1R) agonists have been detailed in a Fortvita Biologics Inc. patent. They are reported to be useful for the treatment of arthritis, coronary heart diseases, dementia, diabetes, hyperlipidemia, inflammatory bowel diseases, obesity and substance abuse and dependence.